Phenibut.

Phenibut acts at GABA-B receptors while kavalactones modulate GABA-A channels, so the two act on the same inhibitory system by different routes. Taken together the sedative and motor-slowing effects add up rather than cancel, which is why they are kept apart rather than stacked.

Valerian constituents increase GABAergic tone at the GABA-A complex, and phenibut already raises inhibitory signalling through GABA-B. Combining them deepens drowsiness and slowed reaction time beyond what either contributes alone.

Picamilon is a niacin conjugate that releases GABA centrally, and phenibut is a GABA analogue in its own right. Stacking them raises inhibitory tone from two routes onto one system, so they are redundant and additive rather than a designed pair.

Theanine shifts glutamate signalling and raises alpha wave activity while phenibut works through GABA-B receptors. The calming effects add together, which formulators account for when setting doses.

Melatonin acts on circadian receptors to lower arousal while phenibut lowers it through inhibitory neurotransmission. The two stack on the same end point of reduced alertness.

Passionflower flavonoids modulate the GABA-A receptor complex while phenibut acts at GABA-B. Both push inhibitory tone in the same direction, so the sedative effect is cumulative.

Honokiol and magnolol from magnolia bark are positive modulators at GABA-A sites, a different subunit family from phenibut's GABA-B action. The combined effect on arousal is additive.

Glycine is itself an inhibitory neurotransmitter at spinal and brainstem receptors, separate from the GABA system phenibut acts on. Both lower net excitatory tone, so they layer.

Magnesium sits in the NMDA receptor channel and damps excitatory signalling while phenibut raises inhibitory signalling. The two arrive at lowered arousal from opposite sides of the same balance.

Caffeine blocks adenosine receptors to raise alertness, which runs against the inhibitory tone phenibut produces. The pairing blunts the sedative side, so it is an opposing pair rather than a designed one.

Phenibut is beta-phenyl-GABA, a GABA molecule carrying a phenyl ring that lets it cross into the central nervous system, where it acts mainly at GABA-B receptors. Oral GABA itself penetrates the brain poorly, so stacking the two is not simply a larger GABA dose. Formulators pair them anyway, and the combination should be read as acting on one receptor family, with any calming effect additive rather than independent.

Taurine binds inhibitory GABA-A and glycine receptors, a different site from the GABA-B receptor phenibut favours. Two inhibitory inputs converging on the same neuronal circuits can sum, so drowsiness and slowed reaction time are the effects to watch when they are taken close together. No combination trial in people has been located, and the pairing rests on receptor pharmacology rather than clinical measurement.

Magnesium sits in the NMDA receptor pore as a voltage-dependent block, damping excitatory glutamate signalling, while phenibut works from the inhibitory side at GABA-B. The two push the excitation to inhibition balance in the same direction by different routes. Read the pairing as mechanistic; the sedation, not a benefit, is the thing to anticipate.

Endogenous GABA is produced when glutamate decarboxylase removes a carboxyl group from glutamate, and that enzyme cannot turn over without pyridoxal 5-phosphate. B6 status therefore sets the ceiling on how much native GABA a person makes. Phenibut acts downstream at the receptor and does not need B6 to work, so this is a supporting relationship for normal inhibitory tone rather than a potentiation of phenibut itself.

P5P is the already-phosphorylated coenzyme, so it skips the pyridoxal kinase step that pyridoxine hydrochloride must pass through. The relationship to GABA synthesis is the same one described for pyridoxine. It supports the body's own inhibitory neurotransmitter production and has no documented direct interaction with phenibut at the receptor.

Chamomile's apigenin is a documented ligand at the benzodiazepine binding site on GABA-A receptors. Phenibut engages GABA-B. Both are inhibitory inputs, so the sedative effect of the pair is reasonably expected to be greater than either alone. That expectation comes from receptor pharmacology, not from a trial of the two together.

Lemon balm constituents slow GABA transaminase, which raises how long endogenous GABA stays in the synapse. Phenibut adds receptor-level agonism on top of that. The two mechanisms are complementary, and the practical consequence is more inhibitory signalling and more sedation than either produces separately.

Ashwagandha extracts act GABA-mimetically in receptor preparations and are used for their calming register. Combined with a GABA-B agonist the sedative load stacks. The evidence here is preclinical receptor work plus common formulation practice, so read it as mechanistic rather than clinical.

5-HTP is decarboxylated to serotonin, which shapes sleep onset and mood tone through its own receptor families. Phenibut does not touch that pathway directly, so any combined effect is two separate calming systems running at once rather than one amplified pathway. Additive drowsiness is the predictable result.

Tryptophan enters the brain on the large neutral amino acid transporter and is hydroxylated to 5-HTP before becoming serotonin. It works on a different axis from phenibut's GABA-B agonism. Taken together the two contribute independently to sleep-onset sedation, which is worth anticipating rather than a documented synergy.

Rhodiola is taken for alertness and perceived energy, while phenibut is taken for the opposite register. Pairing them puts two opposing inputs into the same evening, and the subjective result is unpredictable rather than balanced. There is no combination study; the note exists so a formulator does not assume the two cancel cleanly.